NCT00829179View on ClinicalTrials.gov

Role of RhuMab-E25 in Reducing Exhaled Nitric Oxide (NO) in Allergic Asthma

PHASE3CompletedINTERVENTIONAL
Enrollment

20

Participants

Timeline

Start Date

October 31, 2002

Primary Completion Date

July 31, 2004

Study Completion Date

July 31, 2004

Conditions
Allergic Asthma
Interventions
DRUG

RhuMab-E25

three subcutaneous injections spaced 1 month apart; dose based on subject weight and baseline IgE level.

Trial Locations (1)

27710

Duke University Medical Center, Durham

Sponsors

Lead Sponsor

Duke University

Collaborators (1)

Genentech, Inc.
All Listed Sponsors
collaborator

Genentech, Inc.

INDUSTRY

lead

Duke University

OTHER

NCT00829179 - Role of RhuMab-E25 in Reducing Exhaled Nitric Oxide (NO) in Allergic Asthma | Biotech Hunter | Biotech Hunter